000 01266 a2200373 4500
005 20250514075401.0
264 0 _c20040331
008 200403s 0 0 eng d
022 _a1471-4914
024 7 _a10.1016/s1471-4914(03)00117-5
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aShimohama, Shun
245 0 0 _aDisease model: Parkinson's disease.
_h[electronic resource]
260 _bTrends in molecular medicine
_cAug 2003
300 _a360-5 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650 0 4 _aAnimals
650 0 4 _aAnimals, Genetically Modified
650 0 4 _aApoptosis
_xphysiology
650 0 4 _aDisease Models, Animal
650 0 4 _aDopamine Agents
_xmetabolism
650 0 4 _aHumans
650 0 4 _aMice
_xgenetics
650 0 4 _aNeurotoxins
_xmetabolism
650 0 4 _aParkinson Disease
_xphysiopathology
650 0 4 _aPrimates
650 0 4 _aRats
650 0 4 _aReceptors, Dopamine D2
_xgenetics
700 1 _aSawada, Hideyuki
700 1 _aKitamura, Yoshihisa
700 1 _aTaniguchi, Takashi
773 0 _tTrends in molecular medicine
_gvol. 9
_gno. 8
_gp. 360-5
856 4 0 _uhttps://doi.org/10.1016/s1471-4914(03)00117-5
_zAvailable from publisher's website
999 _c12699840
_d12699840